Advisor Resource Council’s Royalty Pharma RPRX Stock Holding History

Advisor Resource Council’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$911K	Buy	16,003 +101	+0.6%	+$5.26K	0.26%	82
2026 Q1	$763K	Buy	15,902 +750	+5%	+$32.8K	0.25%	84
2025 Q4	$642K	Buy	+15,152	New	+$578K	0.23%	97
2025 Q3	–	Sell	-7,217	Closed	-$260K	–	150
2025 Q2	$260K	Sell	7,217 -83,360	-92%	-$2.76M	0.1%	148
2025 Q1	$2.6M	Buy	+90,577	New	+$2.87M	0.21%	123

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Advisor Resource Council's RPRX Position: Q2 2026 in Review

Advisor Resource Council increased its Royalty Pharma (RPRX) stake by 0.64% in Q2 2026, buying an estimated $5.26K and bringing the position to 16,003 shares worth $911K. The position accounts for 0.26% of the portfolio, ranked #82.

Advisor Resource Council first reported a position in RPRX in Q1 2025 and has held it in 5 quarters since. The position peaked at $2.6M in Q1 2025. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Advisor Resource Council held 16,003 shares of Royalty Pharma worth $911K as of Q2 2026.
Advisor Resource Council bought 101 Royalty Pharma shares in Q2 2026, an estimated $5.26K.
Royalty Pharma made up 0.26% of Advisor Resource Council's portfolio in Q2 2026, its #82 holding.
Advisor Resource Council first reported a position in Royalty Pharma in Q1 2025 and has held it in 5 quarters since.
Advisor Resource Council's Royalty Pharma position peaked at $2.6M in Q1 2025.
645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Advisor Resource Council's 13F filing for Q2 2026, filed 28 Jul 2026.